Our proprietary delivery system (P-glycoprotein (P-gp) pump inhibitor), is a unique technology platform which enables oral absorption of a wide range of effective anticancer drugs which are today only given intravenously due to poor oral absorption. Suppression of the P-gp pump allows certain clinically important compounds (such as, Paclitaxel, Irinotecan, and others), which would normally be effluxed back into the gastrointestinal tract and excreted, to enter the bloodstream and become bioavailable through oral administration. Importantly, the P-gp inhibitor is not systemically absorbed.
This new delivery system allows the cancer patient to receive greater systemic exposure to well-known and proven active pharmaceutical ingredients. We believe this will be a basis to demonstrate an entire platform of superior and safer drugs.